CoChat
Sign Up
Cited by 57

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Therapeutic and Diagnostic Potential of Exosomes as Drug Delivery Systems in Brain Cancer

Avgoulas, Dimitrios I., Tasioulis, Konstantinos S., Papi, Rigini M., Pantazaki, Anastasia A.·2023·Pharmaceutics
DOI 10.3390/pharmaceutics15051439PMC PMC10221347
Open this paper in CoChat — free account

Abstract

Cancer is designated as one of the principal causes of mortality universally. Among different types of cancer, brain cancer remains the most challenging one due to its aggressiveness, the ineffective permeation ability of drugs through the blood–brain barrier (BBB), and drug resistance. To overcome the aforementioned issues in fighting brain cancer, there is an imperative need for designing novel therapeutic approaches. Exosomes have been proposed as prospective “Trojan horse” nanocarriers of anticancer theranostics owing to their biocompatibility, increased stability, permeability, negligible immunogenicity, prolonged circulation time, and high loading capacity. This review provides a comprehensive discussion on the biological properties, physicochemical characteristics, isolation methods, biogenesis and internalization of exosomes, while it emphasizes their therapeutic and diagnostic potential as drug vehicle systems in brain cancer, highlighting recent advances in the research field. A comparison of the biological activity and therapeutic effectiveness of several exosome-encapsulated cargo including drugs and biomacromolecules underlines their great supremacy over the non-exosomal encapsulated cargo in the delivery, accumulation, and biological potency. Various studies on cell lines and animals give prominence to exosome-based nanoparticles (NPs) as a promising and alternative approach in the management of brain cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics15051439

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A representative scheme of exosomal composition. Created with Biorender.com.
Figure 1 A representative scheme of exosomal composition. Created with Biorender.com.CC BY · PubMed Central
Figure 2 Exosome biogenesis and different uptake pathways.
Figure 2 Exosome biogenesis and different uptake pathways.CC BY · PubMed Central
Figure 3 (A) Steps to brain cancer diagnosis utilizing exosomes. (B) Exosomal biomarker groups for brain cancer diagnosis. Created with Biorender.com.
Figure 3 (A) Steps to brain cancer diagnosis utilizing exosomes. (B) Exosomal biomarker groups for brain cancer diagnosis. Created with Biorender.com.CC BY · PubMed Central
Figure 4 A representative scheme of exosome loading and modification methods. Created with Biorender.com.
Figure 4 A representative scheme of exosome loading and modification methods. Created with Biorender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 250

  1. Arrighetti, 2018, Exosome-like Nanovectors for Drug Delivery in Cancer, Curr. Med. Chem., 26, 6132, 10.2174/0929867325666180831150259 · DOI
  2. Romano, E., Netti, P.A., and Torino, E. (2020). Exosomes in Gliomas: Biogenesis, Isolation, and Preliminary Applications in Nanomedicine. Pharmaceuticals, 13. · DOI
  3. Benecke, L., Coray, M., Umbricht, S., Chiang, D., Figueiró, F., and Muller, L. (2021). Exosomes: Small Evs with Large Immunomodulatory Effect in Glioblastoma. Int. J. Mol. Sci., 22. · DOI
  4. Wu, 2021, The Roles of Exosomes as Future Therapeutic Agents and Diagnostic Tools for Glioma, Front. Oncol., 11, 733529, 10.3389/fonc.2021.733529 · DOI
  5. Tang, 2021, Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment, Front. Pharmacol., 12, 786700, 10.3389/fphar.2021.786700 · DOI
  6. Ghaemmaghami, 2020, Role of Exosomes in Malignant Glioma: MicroRNAs and Proteins in Pathogenesis and Diagnosis, Cell Commun. Signal., 18, 120, 10.1186/s12964-020-00623-9 · DOI
  7. Huang, 2022, The Potential Role of Exosomes in the Treatment of Brain Tumors, Recent Updates and Advances, Front. Oncol., 12, 869929, 10.3389/fonc.2022.869929 · DOI
  8. Oliveira, F.D., Castanho, M.A.R.B., and Neves, V. (2021). Exosomes and Brain Metastases: A Review on Their Role and Potential Applications. Int. J. Mol. Sci., 22. · DOI
  9. Zheng, 2022, Exosome-Based Delivery Nanoplatforms: Next-Generation Theranostic Platforms for Breast Cancer, Biomater. Sci., 10, 1607, 10.1039/D2BM00062H · DOI
  10. Halevas, 2022, Flavonoid-Liposomes Formulations: Physico-Chemical Characteristics, Biological Activities and Therapeutic Applications, Eur. J. Med. Chem. Rep., 5, 100059
  11. Batrakova, 2015, Using Exosomes, Naturally-Equipped Nanocarriers, for Drug Delivery, J. Control. Release, 219, 396, 10.1016/j.jconrel.2015.07.030 · DOI · Paper page
  12. Wei, 2021, Regulation of Exosome Production and Cargo Sorting, Int. J. Biol. Sci., 17, 163, 10.7150/ijbs.53671 · DOI · Paper page
  13. Nam, 2020, Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy, Adv. Mater., 32, 2002440, 10.1002/adma.202002440 · DOI
  14. Gurung, 2021, The Exosome Journey: From Biogenesis to Uptake and Intracellular Signalling, Cell Commun. Signal., 19, 47, 10.1186/s12964-021-00730-1 · DOI
  15. Jan, A.T., Rahman, S., Badierah, R., Lee, E.J., Mattar, E.H., Redwan, E.M., and Choi, I. (2021). Expedition into Exosome Biology: A Perspective of Progress from Discovery to Therapeutic Development. Cancers, 13. · DOI
  16. Lyu, 2018, Extracellular Vesicle Directed Exogenous Ion Channel Transport for Precise Manipulation of Biological Events, Bioconjug. Chem., 29, 2715, 10.1021/acs.bioconjchem.8b00377 · DOI
  17. Burtenshaw, 2022, Exosomal Composition, Biogenesis and Profiling Using Point-of-Care Diagnostics—Implications for Cardiovascular Disease, Front. Cell Dev. Biol., 10, 853451, 10.3389/fcell.2022.853451 · DOI
  18. Peng, 2020, Exosome: A Significant Nano-Scale Drug Delivery Carrier, J. Mater. Chem. B, 8, 7591, 10.1039/D0TB01499K · DOI
  19. Zhou, 2020, Application of Exosomes as Liquid Biopsy in Clinical Diagnosis, Signal Transduct. Target. Ther., 5, 144, 10.1038/s41392-020-00258-9 · DOI · Paper page
  20. Yu, 2022, Exosomes as a New Frontier of Cancer Liquid Biopsy, Mol. Cancer, 21, 56, 10.1186/s12943-022-01509-9 · DOI · Paper page
  21. Gao, 2021, Emerging Role of Exosomes in Liquid Biopsy for Monitoring Prostate Cancer Invasion and Metastasis, Front. Cell Dev. Biol., 9, 679527, 10.3389/fcell.2021.679527 · DOI
  22. Gu, Y., Li, M., Wang, T., Liang, Y., Zhong, Z., Wang, X., Zhou, Q., Chen, L., Lang, Q., and He, Z. (2012). Lactation-Related MicroRNA Expression Profiles of Porcine Breast Milk Exosomes. PLoS ONE, 7. · DOI
  23. Rehman, 2023, Exosomes Based Strategies for Brain Drug Delivery, Biomaterials, 293, 121949, 10.1016/j.biomaterials.2022.121949 · DOI
  24. Azami, 2022, Exosome-Based Strategies for Diagnosis and Therapy of Glioma Cancer, Cancer Cell Int., 22, 262, 10.1186/s12935-022-02642-7 · DOI
  25. Katakowski, 2016, Exosomes as Tools to Suppress Primary Brain Tumor, Cell. Mol. Neurobiol., 36, 343, 10.1007/s10571-015-0280-9 · DOI
  26. Zottel, A., Videtič Paska, A., and Jovčevska, I. (2019). Nanotechnology Meets Oncology: Nanomaterials in Brain Cancer Research, Diagnosis and Therapy. Materials, 12. · DOI
  27. Shi, 2020, Role of Exosomes in the Progression, Diagnosis, and Treatment of Gliomas, Med. Sci. Monit., 26, e924023, 10.12659/MSM.924023 · DOI
  28. Masoomzadeh, 2017, Polyphenol Nanoformulations for Cancer Therapy: Experimental Evidence and Clinical Perspective, Int. J. Nanomed., 12, 2689, 10.2147/IJN.S131973 · DOI
  29. Choi, D.G., Venkatesan, J., and Shim, M.S. (2019). Selective Anticancer Therapy Using Pro-Oxidant Drug-Loaded Chitosan–Fucoidan Nanoparticles. Int. J. Mol. Sci., 20. · DOI
  30. Abdelaziz, 2018, Inhalable Particulate Drug Delivery Systems for Lung Cancer Therapy: Nanoparticles, Microparticles, Nanocomposites and Nanoaggregates, J. Control. Release, 269, 374, 10.1016/j.jconrel.2017.11.036 · DOI
  31. Curcio, M., Diaz-Gomez, L., Cirillo, G., Nicoletta, F.P., Leggio, A., and Iemma, F. (2021). Dual-Targeted Hyaluronic Acid/Albumin Micelle-Like Nanoparticles for the Vectorization of Doxorubicin. Pharmaceutics, 13. · DOI
  32. de la Torre, P., Pérez-Lorenzo, M.J., Alcázar-Garrido, Á., and Flores, A.I. (2020). Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments. Molecules, 25. · DOI
  33. AlMalki, 2021, Tannin Nanoparticles (NP99) Enhances the Anticancer Effect of Tamoxifen on ER+ Breast Cancer Cells, J. Renew. Mater., 9, 2077, 10.32604/jrm.2021.016173 · DOI
  34. Hua, 2018, Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization, Front. Pharmacol., 9, 790, 10.3389/fphar.2018.00790 · DOI
  35. Ion, D., Niculescu, A.G., Păduraru, D.N., Andronic, O., Mușat, F., Grumezescu, A.M., and Bolocan, A. (2022). An Up-to-Date Review of Natural Nanoparticles for Cancer Management. Pharmaceutics, 14. · DOI
  36. Raposo, 2013, Extracellular Vesicles: Exosomes, Microvesicles, and Friends, J. Cell Biol., 200, 373, 10.1083/jcb.201211138 · DOI · Paper page
  37. Hood, 2016, Post Isolation Modification of Exosomes for Nanomedicine Applications, Nanomedicine, 11, 1745, 10.2217/nnm-2016-0102 · DOI
  38. Hood, 2012, A Systematic Approach to Exosome-Based Translational Nanomedicine, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 4, 458, 10.1002/wnan.1174 · DOI
  39. You, 2018, Engineering Exosomes: A New Direction for Anticancer Treatment, Am. J. Cancer Res., 8, 1332
  40. Samanta, 2018, Exosomes: New Molecular Targets of Diseases, Acta Pharmacol. Sin., 39, 501, 10.1038/aps.2017.162 · DOI
  41. Jia, 2014, Emerging Technologies in Extracellular Vesicle-Based Molecular Diagnostics, Expert Rev. Mol. Diagn., 14, 307, 10.1586/14737159.2014.893828 · DOI
  42. Yuana, 2014, Co-Isolation of Extracellular Vesicles and High-Density Lipoproteins Using Density Gradient Ultracentrifugation, J. Extracell. Vesicles, 3, 23262, 10.3402/jev.v3.23262 · DOI
  43. Cheruvanky, 2007, Rapid Isolation of Urinary Exosomal Biomarkers Using a Nanomembrane Ultrafiltration Concentrator, Am. J. Physiol. Physiol., 292, F1657, 10.1152/ajprenal.00434.2006 · DOI
  44. Grootemaat, 2014, Single-Step Isolation of Extracellular Vesicles by Size-Exclusion Chromatography, J. Extracell. Vesicles, 3, 23430, 10.3402/jev.v3.23430 · DOI
  45. Deregibus, 2016, Charge-Based Precipitation of Extracellular Vesicles, Int. J. Mol. Med., 38, 1359, 10.3892/ijmm.2016.2759 · DOI
  46. Niu, Z., Pang, R.T.K., Liu, W., Li, Q., Cheng, R., and Yeung, W.S.B. (2017). Polymer-Based Precipitation Preserves Biological Activities of Extracellular Vesicles from an Endometrial Cell Line. PLoS ONE, 12. · DOI
  47. Lobb, 2015, Optimized Exosome Isolation Protocol for Cell Culture Supernatant and Human Plasma, J. Extracell. Vesicles, 4, 27031, 10.3402/jev.v4.27031 · DOI
  48. Li, 2017, Progress in Exosome Isolation Techniques, Theranostics, 7, 789, 10.7150/thno.18133 · DOI
  49. Lee, 2015, Acoustic Purification of Extracellular Microvesicles, ACS Nano, 9, 2321, 10.1021/nn506538f · DOI
  50. Busatto, S., Vilanilam, G., Ticer, T., Lin, W.-L., Dickson, D., Shapiro, S., Bergese, P., and Wolfram, J. (2018). Tangential Flow Filtration for Highly Efficient Concentration of Extracellular Vesicles from Large Volumes of Fluid. Cells, 7. · DOI
  51. Gardiner, 2016, Techniques Used for the Isolation and Characterization of Extracellular Vesicles: Results of a Worldwide Survey, J. Extracell. Vesicles, 5, 32945, 10.3402/jev.v5.32945 · DOI
  52. Tauro, 2012, Comparison of Ultracentrifugation, Density Gradient Separation, and Immunoaffinity Capture Methods for Isolating Human Colon Cancer Cell Line LIM1863-Derived Exosomes, Methods, 56, 293, 10.1016/j.ymeth.2012.01.002 · DOI
  53. Morishita, 2015, Quantitative Analysis of Tissue Distribution of the B16BL6-Derived Exosomes Using a Streptavidin-Lactadherin Fusion Protein and Iodine-125-Labeled Biotin Derivative After Intravenous Injection in Mice, J. Pharm. Sci., 104, 705, 10.1002/jps.24251 · DOI
  54. Smyth, 2015, Biodistribution and Delivery Efficiency of Unmodified Tumor-Derived Exosomes, J. Control. Release, 199, 145, 10.1016/j.jconrel.2014.12.013 · DOI
  55. Haney, 2015, Exosomes as Drug Delivery Vehicles for Parkinson’s Disease Therapy, J. Control. Release, 207, 18, 10.1016/j.jconrel.2015.03.033 · DOI · Paper page
  56. Didiot, 2016, Exosome-Mediated Delivery of Hydrophobically Modified SiRNA for Huntingtin MRNA Silencing, Mol. Ther., 24, 1836, 10.1038/mt.2016.126 · DOI · Paper page
  57. Faruqu, 2019, Membrane Radiolabelling of Exosomes for Comparative Biodistribution Analysis in Immunocompetent and Immunodeficient Mice—A Novel and Universal Approach, Theranostics, 9, 1666, 10.7150/thno.27891 · DOI
  58. Zhang, 2022, Exosomes as Anticancer Drug Delivery Vehicles: Prospects and Challenges, Front. Biosci. Landmark, 27, 293, 10.31083/j.fbl2710293 · DOI
  59. Rezaie, 2022, A Review on Exosomes Application in Clinical Trials: Perspective, Questions, and Challenges, Cell Commun. Signal., 20, 145, 10.1186/s12964-022-00959-4 · DOI
  60. Witwer, 2018, Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines, J. Extracell. Vesicles, 7, 1535750, 10.1080/20013078.2018.1535750 · DOI · Paper page
  61. Cocucci, 2009, Shedding Microvesicles: Artefacts No More, Trends Cell Biol., 19, 43, 10.1016/j.tcb.2008.11.003 · DOI · Paper page
  62. Patil, 2019, Exosomes: Biogenesis, Composition, Functions, and Their Role in Pre-Metastatic Niche Formation, Biotechnol. Bioprocess Eng., 24, 689, 10.1007/s12257-019-0170-y · DOI
  63. Teng, 2021, Shedding Light on Extracellular Vesicle Biogenesis and Bioengineering, Adv. Sci., 8, 2003505, 10.1002/advs.202003505 · DOI
  64. Zhuo, 2020, Circular RNAs in Early Brain Development and Their Influence and Clinical Significance in Neuropsychiatric Disorders, Neural Regen. Res., 15, 817, 10.4103/1673-5374.268969 · DOI
  65. Armstrong, 2018, Strategic Design of Extracellular Vesicle Drug Delivery Systems, Adv. Drug Deliv. Rev., 130, 12, 10.1016/j.addr.2018.06.017 · DOI · Paper page
  66. Kibria, 2018, Exosomes as a Drug Delivery System in Cancer Therapy: Potential and Challenges, Mol. Pharm., 15, 3625, 10.1021/acs.molpharmaceut.8b00277 · DOI
  67. Kalluri, 2020, The Biology, Function, and Biomedical Applications of Exosomes, Science, 367, eaau6977, 10.1126/science.aau6977 · DOI · Paper page
  68. Vahabi, 2022, Tumor Cells-Derived Exosomal CircRNAs: Novel Cancer Drivers, Molecular Mechanisms, and Clinical Opportunities, Biochem. Pharmacol., 200, 115038, 10.1016/j.bcp.2022.115038 · DOI
  69. Lunova, M., Smolková, B., Lynnyk, A., Uzhytchak, M., Jirsa, M., Kubinová, Š., Dejneka, A., and Lunov, O. (2019). Targeting the MTOR Signaling Pathway Utilizing Nanoparticles: A Critical Overview. Cancers, 11. · DOI
  70. Jeppesen, 2019, Reassessment of Exosome Composition, Cell, 177, 428, 10.1016/j.cell.2019.02.029 · DOI · Paper page
  71. Stahl, 2015, Extracellular Vesicles Shuffling Intercellular Messages: For Good or for Bad, Curr. Opin. Cell Biol., 35, 69, 10.1016/j.ceb.2015.04.013 · DOI
  72. Phoonsawat, 2014, Adiponectin Is Partially Associated with Exosomes in Mouse Serum, Biochem. Biophys. Res. Commun., 448, 261, 10.1016/j.bbrc.2014.04.114 · DOI · Paper page
  73. Chen, 2015, Suppression of Fibrogenic Signaling in Hepatic Stellate Cells by Twist1-Dependent MicroRNA-214 Expression: Role of Exosomes in Horizontal Transfer of Twist1, Am. J. Physiol. Liver Physiol., 309, G491
  74. Mathivanan, 2012, ExoCarta 2012: Database of Exosomal Proteins, RNA and Lipids, Nucleic Acids Res., 40, D1241, 10.1093/nar/gkr828 · DOI
  75. Simpson, 2012, ExoCarta as a Resource for Exosomal Research, J. Extracell. Vesicles, 1, 18374, 10.3402/jev.v1i0.18374 · DOI
  76. Kim, 2013, EVpedia: An Integrated Database of High-Throughput Data for Systemic Analyses of Extracellular Vesicles, J. Extracell. Vesicles, 2, 20384, 10.3402/jev.v2i0.20384 · DOI
  77. Subra, 2007, Exosome Lipidomics Unravels Lipid Sorting at the Level of Multivesicular Bodies, Biochimie, 89, 205, 10.1016/j.biochi.2006.10.014 · DOI
  78. Subra, 2010, Exosomes Account for Vesicle-Mediated Transcellular Transport of Activatable Phospholipases and Prostaglandins, J. Lipid Res., 51, 2105, 10.1194/jlr.M003657 · DOI
  79. Zitvogel, 2002, Exosomes: Composition, Biogenesis and Function, Nat. Rev. Immunol., 2, 569, 10.1038/nri855 · DOI
  80. Valadi, 2007, Exosome-Mediated Transfer of MRNAs and MicroRNAs Is a Novel Mechanism of Genetic Exchange between Cells, Nat. Cell Biol., 9, 654, 10.1038/ncb1596 · DOI · Paper page
  81. Skog, 2008, Glioblastoma Microvesicles Transport RNA and Proteins That Promote Tumour Growth and Provide Diagnostic Biomarkers, Nat. Cell Biol., 10, 1470, 10.1038/ncb1800 · DOI · Paper page
  82. Shao, 2020, Advances in Exosome-Based Drug Delivery and Tumor Targeting: From Tissue Distribution to Intracellular Fate, Int. J. Nanomed., 15, 9355, 10.2147/IJN.S281890 · DOI · Paper page
  83. Breakefield, 2013, Extracellular Vesicles: Biology and Emerging Therapeutic Opportunities, Nat. Rev. Drug Discov., 12, 347, 10.1038/nrd3978 · DOI · Paper page
  84. Shaimardanova, 2020, Extracellular Vesicles in the Diagnosis and Treatment of Central Nervous System Diseases, Neural Regen. Res., 15, 586, 10.4103/1673-5374.266908 · DOI
  85. Heusermann, 2016, Exosomes Surf on Filopodia to Enter Cells at Endocytic Hot Spots, Traffic within Endosomes, and Are Targeted to the ER, J. Cell Biol., 213, 173, 10.1083/jcb.201506084 · DOI · Paper page
  86. Wu, 2009, Human Γδ T Cells: A Lymphoid Lineage Cell Capable of Professional Phagocytosis, J. Immunol., 183, 5622, 10.4049/jimmunol.0901772 · DOI
  87. Nabi, 2003, Caveolae/Raft-Dependent Endocytosis, J. Cell Biol., 161, 673, 10.1083/jcb.200302028 · DOI
  88. Joshi, 2020, Endocytosis of Extracellular Vesicles and Release of Their Cargo from Endosomes, ACS Nano, 14, 4444, 10.1021/acsnano.9b10033 · DOI
  89. Andreu, 2014, Tetraspanins in Extracellular Vesicle Formation and Function, Front. Immunol., 5, 442, 10.3389/fimmu.2014.00442 · DOI
  90. Garnier, 2012, Oncogenic Extracellular Vesicles in Brain Tumor Progression, Front. Physiol., 3, 294
  91. Whiteside, 2013, Immune Modulation of T-Cell and NK (Natural Killer) Cell Activities by TEXs (Tumour-Derived Exosomes), Biochem. Soc. Trans., 41, 245, 10.1042/BST20120265 · DOI
  92. Peinado, 2012, Melanoma Exosomes Educate Bone Marrow Progenitor Cells toward a Pro-Metastatic Phenotype through MET, Nat. Med., 18, 883, 10.1038/nm.2753 · DOI · Paper page
  93. Smyth, 2014, Examination of the Specificity of Tumor Cell Derived Exosomes with Tumor Cells in Vitro, Biochim. Biophys. Acta—Biomembr., 1838, 2954, 10.1016/j.bbamem.2014.07.026 · DOI
  94. Rajagopal, 2018, The Origin and Functions of Exosomes in Cancer, Front. Oncol., 8, 66, 10.3389/fonc.2018.00066 · DOI
  95. Vaidya, M., and Sugaya, K. (2020). DNA Associated with Circulating Exosomes as a Biomarker for Glioma. Genes, 11. · DOI
  96. Jafari, 2020, Designer Exosomes: A New Platform for Biotechnology Therapeutics, BioDrugs, 34, 567, 10.1007/s40259-020-00434-x · DOI
  97. Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary, Acta Neuropathol., 131, 803, 10.1007/s00401-016-1545-1 · DOI
  98. McLendon, 2003, Is the Long-Term Survival of Patients with Intracranial Glioblastoma Multiforme Overstated?, Cancer, 98, 1745, 10.1002/cncr.11666 · DOI
  99. Pan, 2019, Delayed Remote Ischemic Preconditioning ConfersRenoprotection against Septic Acute Kidney Injury via Exosomal MiR-21, Theranostics, 9, 405, 10.7150/thno.29832 · DOI
  100. Xiao, J., and Cretoiu, S. (2017). Exosomes in Cardiovascular Diseases. Advances in Experimental Medicine and Biology, Springer. · DOI
  101. Raj, 2012, A Multiplex Quantitative Proteomics Strategy for Protein Biomarker Studies in Urinary Exosomes, Kidney Int., 81, 1263, 10.1038/ki.2012.25 · DOI
  102. Baker, 2006, Evaluating Markers for the Early Detection of Cancer: Overview of Study Designs and Methods, Clin. Trials, 3, 43, 10.1191/1740774506cn130oa · DOI
  103. Properzi, 2013, Exosomes: The Future of Biomarkers in Medicine, Biomark. Med., 7, 769, 10.2217/bmm.13.63 · DOI
  104. Sun, 2018, Tumor Exosomes: A Double-Edged Sword in Cancer Therapy, Acta Pharmacol. Sin., 39, 534, 10.1038/aps.2018.17 · DOI
  105. Maisano, D., Mimmi, S., Russo, R., Fioravanti, A., Fiume, G., Vecchio, E., Nisticò, N., Quinto, I., and Iaccino, E. (2020). Uncovering the Exosomes Diversity: A Window of Opportunity for Tumor Progression Monitoring. Pharmaceuticals, 13. · DOI
  106. Alonso, 2017, DNA Sequences within Glioma-Derived Extracellular Vesicles Can Cross the Intact Blood-Brain Barrier and Be Detected in Peripheral Blood of Patients, Oncotarget, 8, 1416, 10.18632/oncotarget.13635 · DOI · Paper page
  107. Touat, 2015, Emerging Circulating Biomarkers in Glioblastoma: Promises and Challenges, Expert Rev. Mol. Diagn., 15, 1311, 10.1586/14737159.2015.1087315 · DOI
  108. Schwarzenbach, 2014, Clinical Relevance of Circulating Cell-Free MicroRNAs in Cancer, Nat. Rev. Clin. Oncol., 11, 145, 10.1038/nrclinonc.2014.5 · DOI · Paper page
  109. Takahashi, 2015, The Roles of MicroRNAs in Breast Cancer, Cancers, 7, 598, 10.3390/cancers7020598 · DOI · Paper page
  110. Ahir, 2017, MicroRNAs in Glioblastoma Pathogenesis and Therapy: A Comprehensive Review, Crit. Rev. Oncol. Hematol., 120, 22, 10.1016/j.critrevonc.2017.10.003 · DOI
  111. Galardi, 2005, Extensive Modulation of a Set of MicroRNAs in Primary Glioblastoma, Biochem. Biophys. Res. Commun., 334, 1351, 10.1016/j.bbrc.2005.07.030 · DOI · Paper page
  112. Sun, Y., Wang, J., Guo, C., Sai, K., Wang, J., Chen, F., Yang, Q., Chen, Y., Wang, J., and To, T.S. (2014). MiR-181b Sensitizes Glioma Cells to Teniposide by Targeting MDM2. BMC Cancer, 14. · DOI
  113. Chen, 2013, BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 MRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles, Mol. Ther.—Nucleic Acids, 2, e109, 10.1038/mtna.2013.28 · DOI
  114. Siegal, 2016, Dynamics of Circulating Hypoxia-Mediated miRNAs and Tumor Response in Patients with High-Grade Glioma Treated with Bevacizumab, J. Neurosurg., 125, 1008, 10.3171/2015.8.JNS15437 · DOI
  115. Bronisz, 2014, Extracellular Vesicles Modulate the Glioblastoma Microenvironment via a Tumor Suppression Signaling Network Directed by MiR-1, Cancer Res., 74, 738, 10.1158/0008-5472.CAN-13-2650 · DOI · Paper page
  116. Shi, J. (2016). Considering Exosomal MiR-21 as a Biomarker for Cancer. J. Clin. Med., 5. · DOI
  117. Lai, 2015, Serum MicroRNA-210 as a Potential Noninvasive Biomarker for the Diagnosis and Prognosis of Glioma, Br. J. Cancer, 112, 1241, 10.1038/bjc.2015.91 · DOI
  118. Chevillet, 2014, Issues and Prospects of MicroRNA-Based Biomarkers in Blood and Other Body Fluids, Molecules, 19, 6080, 10.3390/molecules19056080 · DOI
  119. Catelan, S., Olioso, D., Santangelo, A., Scapoli, C., Tamanini, A., Pinna, G., Sala, F., Lippi, G., Nicolato, A., and Cabrini, G. (2022). miRNAs in Serum Exosomes for Differential Diagnosis of Brain Metastases. Cancers, 14. · DOI
  120. Manterola, 2014, A Small Noncoding RNA Signature Found in Exosomes of GBM Patient Serum as a Diagnostic Tool, Neuro. Oncol., 16, 520, 10.1093/neuonc/not218 · DOI
  121. White, 1996, Repression of RNA Polymerase III Transcription by the Retinoblastoma Protein, Nature, 382, 88, 10.1038/382088a0 · DOI
  122. (2010). Cabarcas Inhibition of U6 SnRNA Transcription by PTEN. Online J. Biol. Sci., 10, 114–125. · DOI
  123. Marshall, 2008, Non-Coding RNA Production by RNA Polymerase III Is Implicated in Cancer, Nat. Rev. Cancer, 8, 911, 10.1038/nrc2539 · DOI
  124. Su, 2012, Aberrant Expression of MicroRNAs in Gastric Cancer and Biological Significance of MiR-574-3p, Int. Immunopharmacol., 13, 468, 10.1016/j.intimp.2012.05.016 · DOI
  125. Tatarano, 2012, Novel Oncogenic Function of Mesoderm Development Candidate 1 and Its Regulation by MiR-574-3p in Bladder Cancer Cell Lines, Int. J. Oncol., 40, 951, 10.3892/ijo.2011.1294 · DOI
  126. Ebrahimkhani, 2018, Deep Sequencing of Circulating Exosomal MicroRNA Allows Non-Invasive Glioblastoma Diagnosis, npj Precis. Oncol., 2, 28, 10.1038/s41698-018-0071-0 · DOI
  127. Fm, 2015, Differentiation Programs in Glioblastoma, Cold Spring Harb. Lab. Press, 2, 25838542
  128. Jiang, 2010, MiR-182 as a Prognostic Marker for Glioma Progression and Patient Survival, Am. J. Pathol., 177, 29, 10.2353/ajpath.2010.090812 · DOI
  129. Song, 2013, MiR-486 Sustains NF-ΚB Activity by Disrupting Multiple NF-ΚB-Negative Feedback Loops, Cell Res., 23, 274, 10.1038/cr.2012.174 · DOI
  130. Yuan, 2016, MicroRNA-328 Is a Favorable Prognostic Marker in Human Glioma via Suppressing Invasive and Proliferative Phenotypes of Malignant Cells, Int. J. Neurosci., 126, 145, 10.3109/00207454.2014.1002610 · DOI
  131. Huang, 2015, MiR-340 Suppresses Glioblastoma Multiforme, Oncotarget, 6, 9257, 10.18632/oncotarget.3288 · DOI
  132. Xu, 2017, MiR-543 Functions as a Tumor Suppressor in Glioma in Vitro and in Vivo, Oncol. Rep., 38, 725, 10.3892/or.2017.5712 · DOI
  133. Ueda, 2009, Dicer-Regulated MicroRNAs 222 and 339 Promote Resistance of Cancer Cells to Cytotoxic T-Lymphocytes by down-Regulation of ICAM-1, Proc. Natl. Acad. Sci. USA, 106, 10746, 10.1073/pnas.0811817106 · DOI
  134. Lan, 2020, Exosomal MicroRNA-210 Is a Potentially Non-invasive Biomarker for the Diagnosis and Prognosis of Glioma, Oncol. Lett., 19, 1967
  135. Colwell, 2017, Hypoxia in the Glioblastoma Microenvironment: Shaping the Phenotype of Cancer Stem-like Cells, Neuro. Oncol., 19, 887, 10.1093/neuonc/now258 · DOI
  136. Dang, 2015, The Role of Hypoxia-Induced MiR-210 in Cancer Progression, Int. J. Mol. Sci., 16, 6353, 10.3390/ijms16036353 · DOI
  137. Yang, 2017, Biological Implications and Clinical Value of Mir-210 in Gastrointestinal Cancer, Expert Rev. Gastroenterol. Hepatol., 11, 539, 10.1080/17474124.2017.1309281 · DOI
  138. Sun, 2021, Exosomal MiR-2276-5p in Plasma Is a Potential Diagnostic and Prognostic Biomarker in Glioma, Front. Cell Dev. Biol., 9, 671202, 10.3389/fcell.2021.671202 · DOI
  139. Hutagalung, 2011, Role of Rab GTPases in Membrane Traffic and Cell Physiology, Physiol. Rev., 91, 119, 10.1152/physrev.00059.2009 · DOI · Paper page
  140. Clancy, 2012, Tumor-Derived Microvesicles: Shedding Light on Novel Microenvironment Modulators and Prospective Cancer Biomarkers, Genes Dev., 26, 1287, 10.1101/gad.192351.112 · DOI
  141. Hoshino, 2013, Exosome Secretion Is Enhanced by Invadopodia and Drives Invasive Behavior, Cell Rep., 5, 1159, 10.1016/j.celrep.2013.10.050 · DOI
  142. Shao, 2019, MiR-454-3p Is an Exosomal Biomarker and Functions as a Tumor Suppressor in Glioma, Mol. Cancer Ther., 18, 459, 10.1158/1535-7163.MCT-18-0725 · DOI
  143. Vo, 2019, The Landscape of Circular RNA in Cancer, Cell, 176, 869, 10.1016/j.cell.2018.12.021 · DOI
  144. Meng, 2017, CircRNA: Functions and Properties of a Novel Potential Biomarker for Cancer, Mol. Cancer, 16, 94, 10.1186/s12943-017-0663-2 · DOI
  145. Li, 2015, Circular RNA Is Enriched and Stable in Exosomes: A Promising Biomarker for Cancer Diagnosis, Cell Res., 25, 981, 10.1038/cr.2015.82 · DOI
  146. Kaiser, 2018, ‘Liquid Biopsy’ for Cancer Promises Earlydetection, Science, 359, 259, 10.1126/science.359.6373.259 · DOI
  147. Dong, 2016, Identification and Characterization of Human Testis Derived Circular RNAs and Their Existence in Seminal Plasma, Sci. Rep., 6, 39080, 10.1038/srep39080 · DOI
  148. Xu, 2018, NFIX Circular RNA Promotes Glioma Progression by Regulating MiR-34a-5p via Notch Signaling Pathway, Front. Mol. Neurosci., 11, 225, 10.3389/fnmol.2018.00225 · DOI
  149. Zhang, 2018, A Peptide Encoded by Circular Form of LINC-PINT Suppresses Oncogenic Transcriptional Elongation in Glioblastoma, Nat. Commun., 9, 4475, 10.1038/s41467-018-06862-2 · DOI
  150. Yin, 2020, CircMMP1promotes the Progression of Glioma through MiR-433 HMGB3 Axis in Vitro and in Vivo, IUBMB Life, 72, 2508, 10.1002/iub.2383 · DOI
  151. Li, 2022, Circular RNA Sequencing Reveals Serum Exosome Circular RNA Panel for High-Grade Astrocytoma Diagnosis, Clin. Chem., 68, 332, 10.1093/clinchem/hvab254 · DOI
  152. Thakur, 2014, Double-Stranded DNA in Exosomes: A Novel Biomarker in Cancer Detection, Cell Res., 24, 766, 10.1038/cr.2014.44 · DOI
  153. Yang, 2017, DNM3, P65 and P53 from Exosomes Represent Potential Clinical Diagnosis Markers for Glioblastoma Multiforme, Ther. Adv. Med. Oncol., 9, 741, 10.1177/1758834017737471 · DOI
  154. Manda, 2018, Exosomes as a Biomarker Platform for Detecting Epidermal Growth Factor Receptor-Positive High-Grade Gliomas, J. Neurosurg., 128, 1091, 10.3171/2016.11.JNS161187 · DOI
  155. Chen, 2018, Exosomal PD-L1 Contributes to Immunosuppression and Is Associated with Anti-PD-1 Response, Nature, 560, 382, 10.1038/s41586-018-0392-8 · DOI · Paper page
  156. Francisco, 2009, PD-L1 Regulates the Development, Maintenance, and Function of Induced Regulatory T Cells, J. Exp. Med., 206, 3015, 10.1084/jem.20090847 · DOI
  157. Litak, J., Mazurek, M., Grochowski, C., Kamieniak, P., and Roliński, J. (2019). PD-L1/PD-1 Axis in Glioblastoma Multiforme. Int. J. Mol. Sci., 20. · DOI
  158. Shao, 2015, Chip-Based Analysis of Exosomal MRNA Mediating Drug Resistance in Glioblastoma, Nat. Commun., 6, 6999, 10.1038/ncomms7999 · DOI
  159. Chun, S., Ahn, S., Yeom, C.H., and Park, S. (2016). Exosome Proteome of U-87MG Glioblastoma Cells. Biology, 5. · DOI
  160. Burgeson, R.E. (1987). Structure and Function of Collagen Types, Elsevier.
  161. Stenbeck, 1993, Beta′-COP, a Novel Subunit of Coatomer, EMBO J., 12, 2841, 10.1002/j.1460-2075.1993.tb05945.x · DOI
  162. Markoff, 2007, Annexin A5 Interacts with Polycystin-1 and Interferes with the Polycystin-1 Stimulated Recruitment of E-Cadherin into Adherens Junctions, J. Mol. Biol., 369, 954, 10.1016/j.jmb.2007.03.070 · DOI
  163. Naryzhny, S., Volnitskiy, A., Kopylov, A., Zorina, E., Kamyshinsky, R., Bairamukov, V., Garaeva, L., Shlikht, A., and Shtam, T. (2020). Proteome of Glioblastoma-Derived Exosomes as a Source of Biomarkers. Biomedicines, 8. · DOI
  164. Daido, 2005, Inhibition of the DNA-Dependent Protein Kinase Catalytic Subunit Radiosensitizes Malignant Glioma Cells by Inducing Autophagy, Cancer Res., 65, 4368, 10.1158/0008-5472.CAN-04-4202 · DOI
  165. Jiang, 2013, Valosin-Containing Protein Regulates the Proteasome-Mediated Degradation of DNA-PKcs in Glioma Cells, Cell Death Dis., 4, e647, 10.1038/cddis.2013.171 · DOI
  166. Lara, 2011, MVP and Vaults: A Role in the Radiation Response, Radiat. Oncol., 6, 148, 10.1186/1748-717X-6-148 · DOI
  167. Stavrovskaya, 2016, Problems of Glioblastoma Multiforme Drug Resistance, Biochem., 81, 91
  168. Cui, 2010, Gli1 Is a Potential Target for Alleviating Multidrug Resistance of Gliomas, J. Neurol. Sci., 288, 156, 10.1016/j.jns.2009.09.006 · DOI
  169. Volnitskiy, A., Shtam, T., Burdakov, V., Kovalev, R., Konev, A., and Filatov, M. (2019). Abnormal Activity of Transcription Factors Gli in High-Grade Gliomas. PLoS ONE, 14. · DOI
  170. Peterson, 2019, Isolation and Analysis of Plasma-Derived Exosomes in Patients With Glioma, Front. Oncol., 9, 651, 10.3389/fonc.2019.00651 · DOI
  171. Qiu, 2019, Detection of Glioma-Derived Exosomes with the Biotinylated Antibody-Functionalized Titanium Nitride Plasmonic Biosensor, Adv. Funct. Mater., 29, 1806761, 10.1002/adfm.201806761 · DOI
  172. Salomon, C., Ryan, J., Sobrevia, L., Kobayashi, M., Ashman, K., Mitchell, M., and Rice, G.E. (2013). Exosomal Signaling during Hypoxia Mediates Microvascular Endothelial Cell Migration and Vasculogenesis. PLoS ONE, 8. · DOI
  173. Pucci, 2019, Innovative Approaches for Cancer Treatment: Current Perspectives and New Challenges, Ecancermedicalscience, 13, 961, 10.3332/ecancer.2019.961 · DOI
  174. Zugazagoitia, 2016, Current Challenges in Cancer Treatment, Clin. Ther., 38, 1551, 10.1016/j.clinthera.2016.03.026 · DOI
  175. Li, C., Li, Y., Li, G., and Wu, S. (2022). Functional Nanoparticles for Enhanced Cancer Therapy. Pharmaceutics, 14. · DOI
  176. Kim, H., Jang, H., Cho, H., Choi, J., Hwang, K.Y., Choi, Y., Kim, S.H., and Yang, Y. (2021). Recent Advances in Exosome-based Drug Delivery for Cancer Therapy. Cancers, 13. · DOI · Paper page
  177. Chen, 2022, Exosomes as Drug Carriers in Anti-Cancer Therapy, Front. Cell Dev. Biol., 10, 728616, 10.3389/fcell.2022.728616 · DOI
  178. Walker, 2019, Extracellular Vesicle-Based Drug Delivery Systems for Cancer Treatment, Theranostics, 9, 8001, 10.7150/thno.37097 · DOI
  179. Piffoux, 2018, Modification of Extracellular Vesicles by Fusion with Liposomes for the Design of Personalized Biogenic Drug Delivery Systems, ACS Nano, 12, 6830, 10.1021/acsnano.8b02053 · DOI
  180. Zou, 2018, Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine, Adv. Mater., 30, 1803717, 10.1002/adma.201803717 · DOI · Paper page
  181. Vader, 2016, Extracellular Vesicles for Drug Delivery, Adv. Drug Deliv. Rev., 106, 148, 10.1016/j.addr.2016.02.006 · DOI · Paper page
  182. Akuma, 2019, Naturally Occurring Exosome Vesicles as Potential Delivery Vehicle for Bioactive Compounds, Front. Sustain. Food Syst., 3, 23, 10.3389/fsufs.2019.00023 · DOI
  183. Luan, 2017, Engineering Exosomes as Refined Biological Nanoplatforms for Drug Delivery, Acta Pharmacol. Sin., 38, 754, 10.1038/aps.2017.12 · DOI
  184. Butreddy, A., Kommineni, N., and Dudhipala, N. (2021). Exosomes as Naturally Occurring Vehicles for Delivery of Biopharmaceuticals: Insights from Drug Delivery to Clinical Perspectives. Nanomaterials, 11. · DOI
  185. Lee, 2022, Exosome-Based Drug Delivery Systems and Their Therapeutic Applications, RSC Adv., 12, 18475, 10.1039/D2RA02351B · DOI
  186. Liu, Q., Li, S., Dupuy, A., Le Mai, H., Sailliet, N., Logé, C., Robert, J.M.H., and Brouard, S. (2021). Exosomes as New Biomarkers and Drug Delivery Tools for the Prevention and Treatment of Various Diseases: Current Perspectives. Int. J. Mol. Sci., 22. · DOI
  187. Ghasempour, 2022, Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Strategy in the Brain Tumors, Stem Cell Res. Ther., 13, 1, 10.1186/s13287-022-03212-4 · DOI
  188. Tibensky, M., Jakubechova, J., Altanerova, U., Pastorakova, A., Rychly, B., Baciak, L., Mravec, B., and Altaner, C. (2022). Gene-Directed Enzyme/Prodrug Therapy of Rat Brain Tumor Mediated by Human Mesenchymal Stem Cell Suicide Gene Extracellular Vesicles In Vitro and In Vivo. Cancers, 14. · DOI
  189. Lee, 2013, Mesenchymal Stem Cells Deliver Synthetic MicroRNA Mimics to Glioma Cells and Glioma Stem Cells and Inhibit Their Cell Migration and Self-Renewal, Oncotarget, 4, 346, 10.18632/oncotarget.868 · DOI
  190. Munoz, 2013, Delivery of Functional Anti-MiR-9 by Mesenchymal Stem Cell-Derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity, Mol. Ther.—Nucleic Acids, 2, e126, 10.1038/mtna.2013.60 · DOI
  191. Yan, 2021, Exosomes Derived from MicroRNA-512-5p-Transfected Bone Mesenchymal Stem Cells Inhibit Glioblastoma Progression by Targeting JAG1, Aging, 13, 9911, 10.18632/aging.202747 · DOI
  192. Yu, 2019, Exosomes Derived from MicroRNA-199a-Overexpressing Mesenchymal Stem Cells Inhibit Glioma Progression by down-Regulating AGAP2, Aging, 11, 5300, 10.18632/aging.102092 · DOI
  193. Zhang, 2021, MicroRNA-29a-3p Delivery via Exosomes Derived from Engineered Human Mesenchymal Stem Cells Exerts Tumour Suppressive Effects by Inhibiting Migration and Vasculogenic Mimicry in Glioma, Aging, 13, 5055, 10.18632/aging.202424 · DOI
  194. Xu, 2019, Mesenchymal Stem Cell-Derived Exosomal MicroRNA-133b Suppresses Glioma Progression via Wnt/β-Catenin Signaling Pathway by Targeting EZH2, Stem Cell Res. Ther., 10, 381, 10.1186/s13287-019-1446-z · DOI
  195. Kim, 2018, Exosomes Derived from MicroRNA-584 Transfected Mesenchymal Stem Cells: Novel Alternative Therapeutic Vehicles for Cancer Therapy, BMB Rep., 51, 406, 10.5483/BMBRep.2018.51.8.105 · DOI
  196. Katakowski, 2013, Exosomes from Marrow Stromal Cells Expressing MiR-146b Inhibit Glioma Growth, Cancer Lett., 335, 201, 10.1016/j.canlet.2013.02.019 · DOI · Paper page
  197. Parsaei, 2022, Exosomes to Control Glioblastoma Multiforme: Investigating the Effects of Mesenchymal Stem Cell-Derived Exosomes on C6 Cells in Vitro, Cell Biol. Int., 46, 2028, 10.1002/cbin.11884 · DOI
  198. Rehman, 2022, Heme Oxygenase-1 Targeting Exosomes for Temozolomide Resistant Glioblastoma Synergistic Therapy, J. Control. Release, 345, 696, 10.1016/j.jconrel.2022.03.036 · DOI
  199. Lang, 2018, Mesenchymal Stem Cells as Natural Biofactories for Exosomes Carrying MiR-124a in the Treatment of Gliomas, Neuro. Oncol., 20, 380, 10.1093/neuonc/nox152 · DOI
  200. Valipour, 2022, The Anti-Angiogenic Effect of Atorvastatin Loaded Exosomes on Glioblastoma Tumor Cells: An in Vitro 3D Culture Model, Microvasc. Res., 143, 104385, 10.1016/j.mvr.2022.104385 · DOI

200 of 250 shown

Cited by

Sorted by citations

See all 57

Metadata

Authors
Avgoulas, D. I., Tasioulis, K. S., Papi, R. M., & Pantazaki, A. A.
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2023-05-08
Volume
15
Issue
5
Pages
1439
ISSN
1999-4923
DOI
10.3390/pharmaceutics15051439
PMC
PMC10221347
Cited by
57
References
16
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review